Edwards Lifesciences Corporation $EW Stock Position Raised by Resonant Capital Advisors LLC

Resonant Capital Advisors LLC raised its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 16.0% in the second quarter, Holdings Channel reports. The firm owned 3,886 shares of the medical research company’s stock after buying an additional 536 shares during the period. Resonant Capital Advisors LLC’s holdings in Edwards Lifesciences were worth $304,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its stake in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock worth $2,170,000 after purchasing an additional 145 shares in the last quarter. Pacific Capital Partners Ltd purchased a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $1,760,000. Czech National Bank raised its stake in shares of Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after acquiring an additional 7,917 shares in the last quarter. Mirova US LLC raised its stake in shares of Edwards Lifesciences by 56.2% in the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after acquiring an additional 1,054,301 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC raised its stake in shares of Edwards Lifesciences by 111.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 163,202 shares of the medical research company’s stock valued at $12,532,000 after acquiring an additional 86,186 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EW has been the topic of a number of recent analyst reports. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Wells Fargo & Company lifted their price target on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research report on Thursday, August 7th. Robert W. Baird lifted their price target on Edwards Lifesciences from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, July 25th. Mizuho lifted their price objective on Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Finally, Barclays lifted their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $87.06.

Edwards Lifesciences Trading Up 6.5%

Shares of EW opened at $81.06 on Tuesday. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $64.89 and a 12-month high of $83.04. The firm has a market capitalization of $47.59 billion, a PE ratio of 11.66, a price-to-earnings-growth ratio of 3.65 and a beta of 1.05. The stock’s fifty day simple moving average is $77.42 and its 200-day simple moving average is $76.56.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.29% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.